Pedersen T R
N Engl J Med. 1985 Oct 24;313(17):1055-8. doi: 10.1056/NEJM198510243131705.
The original Norwegian Multicenter Study on Timolol after Myocardial Infarction was a double-blind, randomized study comparing the effect of timolol with that of placebo for up to 33 months after acute myocardial infarction. The initial results showed that the cumulated mortality rate was 39.4 per cent lower among 945 patients randomly assigned to timolol treatment than among 939 patients randomly assigned to placebo (P = 0.0003). After the end of the double-blind period the majority of participating patients in the timolol group continued to receive beta-adrenergic blockade, whereas the majority of placebo-treated patients continued without such blockade. During an extended follow-up of participating patients up to 72 months after randomization, the mortality curves of the two groups continued to rise in parallel. Cumulated mortality rates were 32.3 per cent in the placebo group and 26.4 per cent in the timolol group (P = 0.0028). We conclude that the previously observed early beneficial effect of beta-adrenergic blocking therapy is maintained for at least six years after infarction.
最初的挪威心肌梗死后噻吗洛尔多中心研究是一项双盲随机研究，比较了急性心肌梗死后长达33个月内噻吗洛尔与安慰剂的效果。初步结果显示，945例随机分配接受噻吗洛尔治疗的患者累积死亡率比939例随机分配接受安慰剂治疗的患者低39.4%（P = 0.0003）。双盲期结束后，噻吗洛尔组的大多数参与患者继续接受β-肾上腺素能阻滞剂治疗，而大多数接受安慰剂治疗的患者则继续不接受此类阻滞剂治疗。在对参与患者进行长达随机分组后72个月的延长随访期间，两组的死亡率曲线继续平行上升。安慰剂组的累积死亡率为32.3%，噻吗洛尔组为26.4%（P = 0.0028）。我们得出结论，β-肾上腺素能阻滞剂治疗先前观察到的早期有益效果在心肌梗死后至少六年内持续存在。
